iNtRON Biotechnology, Inc.

As of March 31, 2026, iNtRON Biotechnology, Inc. carries a market capitalization of 126.04B, placing it among publicly traded companies globally. Its enterprise value stands at 94.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

iNtRON Biotechnology, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of March 31, 2026, iNtRON Biotechnology, Inc. has 30.89M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 20.21, and the price-to-book ratio stands at 1.96.

These figures are as of March 31, 2026. The EV/Sales ratio of 14.68 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 94.50B versus a market cap of 126.04B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, iNtRON Biotechnology, Inc. maintains a current ratio of 9.81, meaning it holds 9.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.89, indicating elevated leverage, while an interest coverage ratio of -54.22 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, iNtRON Biotechnology, Inc. posted a negative return on equity (ROE) of -13.01, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.99, reflecting losses generated across the asset base. The company generates approximately 85.26M in revenue per employee across its workforce of 75.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.34 indicates how many times iNtRON Biotechnology, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, iNtRON Biotechnology, Inc. recorded an income tax benefit of -101.63M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -9.29B and -9.19B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, iNtRON Biotechnology, Inc.'s stock has declined approximately 12.80% over the past 52 weeks. The 50-day moving average sits at 2,821.20, while the 200-day moving average is 3,243.13.

Over the twelve months ended March 31, 2026, iNtRON Biotechnology, Inc. generated 6.44B in revenue and converted that into -9.19B in net income, yielding earnings per share of -288.21. EBITDA reached -6.31B, while operating income came in at -8.23B.

As of March 31, 2026, iNtRON Biotechnology, Inc. holds 36.62B in cash and equivalents against 5.08B in total debt, resulting in a net debt position of -20.26B. Total book value stands at 64.43B, with working capital of 36.65B providing operational flexibility.

iNtRON Biotechnology, Inc. produced -9.27B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -2.24B in capital expenditures, free cash flow totaled -11.51B - equivalent to -361.03 per share.

Over the twelve months ended March 31, 2026, iNtRON Biotechnology, Inc. posted a gross margin of 51.89, reflecting its pricing power and cost economics. The operating margin of -127.86 and net profit margin of -142.74 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, iNtRON Biotechnology, Inc. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -8.85: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.63, meaning iNtRON Biotechnology, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

iNtRON Biotechnology, Inc.'s most recent stock split took place on January 10, 2019 with a 1:2 split ratio.

As of March 31, 2026, iNtRON Biotechnology, Inc. has an Altman Z-Score of 12.60, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.